Oncolytic adenovirus

Adenovirus varieties have been explored extensively as a viral vector for gene therapy and also as an oncolytic virus.

Of the many different viruses being explored for oncolytic potential, an adenovirus was the first to be approved by a regulatory agency, the genetically modified H101 strain. It gained regulatory approval in 2005 from China's State Food and Drug Administration (SFDA) for the treatment of head and neck cancer.